Lumenis launches UltraPulse DUO at 119th AAO-HNSF Annual Meeting

To Meet the Increasing ENT Surgical Challenges, the UltraPulse DUO Enables Surgeons to Perform and Complete Any Challenging Operation

Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.

Continuing to innovate in the laser technology space, Lumenis' UltraPulse CO2 laser platform is considered to be the industry gold standard solution for minimally invasive proceduresfor over three decades. Featuring superior precision and high-end performance technology, the UltraPulse DUO provides surgeons with the option to easily shift between free beam and fiber energy deliveries all within the same platform. This unique energy delivery combination allows for the superior precision needed to protect delicate tissue and the extended flexibility required for targeting difficult-to-reach anatomy.

"While scanning free beam technology is the gold standard for CO2 laser surgery, ENT surgeons are often faced with patients who have access challenges to line-of-sight techniques, including the distal airway, that cannot be addressed with one single laser modality," said Paul Castellanos, M.D., Associate Professor of Surgery at the University of Alabama at Birmingham. "With the scanning free beam and fiber integration in one CO2 laser solution, only available in the UltraPulse DUO, I am able to deliver unparalleled treatments throughout the larynx and aero digestive tract with full flexibility and precision."

During oncological procedures, clean and clear margins are valued in pathology and are a key goal in today's operating room. The UltraPulse DUO generates clear margin visibility that can lead to better oncological outcomes. Patients undergoing treatment with UltraPulse DUO may benefit from fewer adverse events, such as adhesions and quicker recovery time, because of the system's capability to highly preserve adjacent delicate and healthy tissue.

As a true combination of the Digital AcuBlade™ Scanning Micromanipulator and the FiberLase™ CO2 laser fiber, the platform provides surgeons with an optimal laser solution with its short learning curve and featuring the market's only system with an adjustable aiming beam and a renewable tip.

"Lumenis is proud to introduce the UltraPulse DUO, a system developed in part with physicians, as a testament to our ongoing collaboration and commitment to surgeons and patients worldwide," said Tzipi Ozer-Armon, CEO of Lumenis. "With our commitment to enhance clinical performance and care, along with our sensitivity to our economic environment, this advanced product platform can benefit surgeons and their healthcare facilities. The UltraPulse DUO addresses multiple indications and enables ENT surgeons to extend their performance from the operating room to the outpatient environment, leading to cost savings and reduction in general anesthesia risks."


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Lumenis Inc.. (2019, June 19). Lumenis launches UltraPulse DUO at 119th AAO-HNSF Annual Meeting. News-Medical. Retrieved on May 28, 2022 from

  • MLA

    Lumenis Inc.. "Lumenis launches UltraPulse DUO at 119th AAO-HNSF Annual Meeting". News-Medical. 28 May 2022. <>.

  • Chicago

    Lumenis Inc.. "Lumenis launches UltraPulse DUO at 119th AAO-HNSF Annual Meeting". News-Medical. (accessed May 28, 2022).

  • Harvard

    Lumenis Inc.. 2019. Lumenis launches UltraPulse DUO at 119th AAO-HNSF Annual Meeting. News-Medical, viewed 28 May 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
U.S. PTO reexamining Lumenis patents